Immulina 800MG Tablet (Pidotimod)

Description

Immulina 800MG Tablet (Pidotimod) — Complete Clinical and Patient Information Guide

Product Overview

Immulina 800MG Tablet (Pidotimod) contains Pidotimod 800mg as its active pharmaceutical ingredient, belonging to the synthetic immunostimulant dipeptide — innate and adaptive immune enhancer. It is clinically indicated for prophylaxis and adjunct treatment of recurrent respiratory tract infections (RTIs) — particularly in children and immunocompromised individuals with frequent upper and lower respiratory infections. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. Cancer and specialty medications require specialist initiation and monitoring — this information is educational and does not replace professional medical guidance.

Immulina 800mg provides pidotimod — the synthetic immunostimulant dipeptide for reducing the burden of recurrent respiratory infections through enhancement of both innate and adaptive immune function.

Mechanism of Action

Pidotimod is a synthetic dipeptide biological response modifier (immunostimulant). It activates the innate immune system through TLR2 receptor engagement and enhances adaptive immunity through promotion of T-lymphocyte differentiation, particularly towards Th1 (cellular immunity) phenotype. Pidotimod increases production of IL-12 and IFN-gamma, enhances natural killer (NK) cell activity, and promotes dendritic cell maturation. It is used as an immunostimulant adjunct in recurrent respiratory tract infections in children and elderly patients — clinical studies suggest reduced frequency and severity of RTIs during winter seasons with prophylactic pidotimod. Available as 400mg and 800mg tablets (Immulina).

Clinical Indications

Immulina 800MG Tablet (Pidotimod) is indicated for prophylaxis and adjunct treatment of recurrent respiratory tract infections (RTIs) — particularly in children and immunocompromised individuals with frequent upper and lower respiratory infections. Specialist confirmation of diagnosis, eligibility for treatment, and initiation of therapy are mandatory — self-diagnosis and self-treatment of these conditions can be dangerous and may delay or undermine appropriate clinical management.

Dosage and Administration

Adults: Immulina 800mg twice daily during acute illness, then once daily for maintenance prophylaxis. Children: 400mg twice daily initially then once daily. Typically given for seasonal prophylaxis (winter months). Take at regular intervals.

Contraindications

Hypersensitivity to pidotimod. No absolute contraindications at standard doses.

Drug Interactions

No significant pharmacokinetic drug interactions reported at standard therapeutic doses.

Adverse Effects

Generally very well tolerated. Rare: GI effects (nausea, abdominal discomfort). Very rare: allergic reactions. Rash.

Special Population Considerations

Immulina (Alfa Wassermann/Zuventus) is the originator brand pidotimod — with clinical studies demonstrating reduced frequency and duration of upper and lower respiratory tract infections with prophylactic use in children. Pidotimod should be viewed as an immunostimulant adjunct, not a replacement for standard medical management of acute infections. Evidence basis: systematic reviews suggest modest but consistent reductions in RTI frequency in paediatric populations.

Storage

Store Immulina 800mg per manufacturer guidelines. Most oral tablets at room temperature (15–25°C) away from heat, light, and moisture. Injectable medications require refrigeration or specific temperature control — follow pharmacy instructions. Keep out of reach of children and dispose of expired medications through authorised pharmaceutical take-back services.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Injectable oncology medications require specialised storage — follow manufacturer and pharmacy guidance. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: For most medications: take as soon as you remember unless it is nearly time for the next dose. Never double-dose. For oncology medications, missed doses should be discussed with your oncologist before taking. Do not stop cancer medications without oncologist guidance.

Q: When should pidotimod be started for respiratory infection prevention?
A: Pidotimod prophylaxis is typically initiated at the beginning of the respiratory infection season (autumn/early winter) and continued for 2–3 months. An acute treatment phase (twice daily) for 7–14 days at the start of each respiratory infection followed by once-daily maintenance provides both treatment and prophylactic benefit. Consult your physician about the optimal timing and duration for your specific situation.

Evidence Base, Regulatory Status, and Quality Standards

The active ingredient in Immulina 800mg has been evaluated in clinical trials and regulatory submissions reviewed by competent health authorities. Oncology and specialty medications are subject to stringent regulatory scrutiny given their risk-benefit profiles in serious conditions. Major oncology guidelines from ESMO, ASCO, NCCN, and relevant national bodies inform prescribing decisions. All medications should be obtained through licensed, regulated pharmacies with valid prescriptions from registered specialists to ensure receipt of authentic, quality-assured products. GMP compliance ensures consistent product quality, identity, strength, and purity.

Cancer and Specialty Medicine Clinical Context

Cancer represents the second leading cause of death globally, accounting for approximately 10 million deaths annually. Modern oncology has been transformed by targeted therapy — drugs designed around specific molecular alterations in cancer cells (BCR-ABL in CML, HER2 in breast cancer, EGFR/ALK in NSCLC, VEGFR in solid tumours) achieving outcomes unimaginable with conventional chemotherapy. The era of precision oncology requires molecular profiling of each patient’s tumour before prescribing targeted agents — EGFR testing for erlotinib/gefitinib, HER2 testing for trastuzumab, ALK testing for ceritinib, and BCR-ABL for imatinib.

Conventional chemotherapy agents (paclitaxel, carboplatin, cyclophosphamide, fluorouracil, epirubicin, oxaliplatin, irinotecan, gemcitabine, dacarbazine, cytarabine, etoposide) remain essential backbones of cancer treatment — often combined with targeted agents in multi-drug regimens. Their cytotoxic mechanisms targeting rapidly dividing cells inevitably affect normal bone marrow, GI mucosa, and hair follicles — explaining myelosuppression, mucositis, and alopecia as class-wide adverse effects that require supportive care.

Haematological malignancies — leukaemias, lymphomas, multiple myeloma — represent a distinct oncological domain where molecular-targeted drugs have achieved remarkable results: imatinib transformed CML from a uniformly fatal disease to one with near-normal life expectancy; rituximab dramatically improved lymphoma outcomes; and the IMiD class (thalidomide, lenalidomide, pomalidomide) has progressively extended myeloma survival.

Parasitic Disease and Tropical Medicine Context

Parasitic infections cause enormous global morbidity — lymphatic filariasis affects 120 million people causing disfiguring lymphoedema; onchocerciasis blinds millions in sub-Saharan Africa; intestinal helminths impair growth and cognition in hundreds of millions of children; scabies infects approximately 200 million people globally; and Giardia/Cryptosporidium cause millions of diarrhoeal episodes annually. Ivermectin, albendazole, mebendazole, and DEC are WHO Essential Medicines — available for low cost and capable of eliminating these diseases when deployed through mass drug administration programmes.

Evidence Base and Quality Standards

The active ingredients in this product range have been evaluated in landmark clinical trials forming the evidence base for modern oncology, infectious disease, and specialty medicine: IPASS (gefitinib in EGFR-mutant NSCLC), ALEX (alectinib in ALK+ NSCLC), BOLERO-2 (everolimus+exemestane), ATAC (anastrozole), COU-AA-301/302 (abiraterone), AFFIRM/PREVAIL (enzalutamide), INPULSIS (nintedanib), ASTRAL-1 to 4 (sofosbuvir/velpatasvir), and many others. GMP-compliant manufacturing ensures consistent pharmaceutical quality. Patients must obtain oncology and specialty medications from licensed pharmacies with valid prescriptions from registered specialists.

Patient Safety, Monitoring, and Adherence

Oncology and specialty pharmacotherapy requires active patient engagement for optimal outcomes. Adherence to oral cancer drugs is critical — missed doses of TKIs like imatinib, erlotinib, and enzalutamide directly reduce drug exposure and potentially allow tumour progression or drug resistance development. Studies in CML show that patients with <80% imatinib adherence have significantly worse molecular response rates and higher transformation risk. The same principle applies to endocrine therapy for breast cancer — patients discontinuing anastrozole or tamoxifen early have substantially higher recurrence rates. Adherence support, side effect management, and patient education are as important as drug selection.

Monitoring requirements for specialty medications are stringent and non-negotiable. FBC monitoring during chemotherapy and methotrexate therapy prevents life-threatening myelosuppression complications. LFT monitoring during TKI and anthracycline therapy detects hepatotoxicity before it becomes severe. Cardiac monitoring during trastuzumab and anthracycline therapy prevents irreversible cardiomyopathy. Molecular monitoring (BCR-ABL PCR, HCV RNA, HBV DNA) determines treatment response and guides duration decisions.

All patients on oncology and specialty medications benefit from structured support: specialist oncology nurse coordination, patient support groups, pharmacist medication counselling, and regular specialist review. Complex medication regimens should be clearly written, explained verbally, and reviewed at each clinical encounter to identify any confusion, interactions, or emerging side effects requiring management.

Responsible Use and Safe Disposal

Oncology medications — particularly oral cytotoxic agents (cyclophosphamide, capecitabine, temozolomide, methotrexate) — are hazardous drugs requiring careful handling. Pregnant women and those planning pregnancy should not handle broken or crushed oral cytotoxic tablets. Unused or expired medications must be returned to a licensed pharmacy for safe hazardous pharmaceutical disposal — never disposed of in household waste or toilet.

Multi-Disciplinary Oncology Care

Modern cancer management requires multi-disciplinary team (MDT) decision-making — integrating oncologists, surgeons, radiologists, pathologists, specialist nurses, and pharmacists to develop individualised treatment plans. Pharmacological therapy (chemotherapy, targeted agents, endocrine therapy, immunotherapy) is one component of comprehensive cancer care alongside surgery (with curative intent for localised disease), radiotherapy (definitive, adjuvant, or palliative), and supportive/palliative care. Clinical trials offer access to novel therapies and the opportunity to advance cancer treatment knowledge — eligible patients should be offered trial participation where available.

Oncology pharmacy practice has become a specialised discipline — oncology pharmacists review complex multi-drug regimens for interactions and dosing errors, prepare hazardous IV chemotherapy safely, counsel patients on managing side effects of oral cancer drugs, and monitor for drug-induced toxicities. The safe use of oncology medications depends on this specialised expertise at every step from prescription to administration.

Palliative and supportive care integration is equally important — managing cancer symptoms (pain, nausea, fatigue, dyspnoea) and treatment side effects (chemotherapy-induced nausea, peripheral neuropathy, immunosuppression, mucositis) maintains quality of life throughout the cancer journey. Early palliative care integration (not just end-of-life care) improves patient outcomes and quality of life even in patients receiving active curative therapy.

Drug Supply and Authentic Procurement

For oncology and specialty medicines, procurement from authenticated, licensed sources is critically important. Counterfeit cancer medications are a documented global public health problem — they range from diluted products (containing less active ingredient than labelled, providing inadequate treatment) to products containing no active ingredient, to products with contaminated or substituted ingredients causing direct harm. Always obtain cancer medications from licensed, regulated pharmacies with valid prescriptions. Indian regulatory authority (CDSCO) oversight and manufacturer GMP compliance provide assurance of product quality for domestically produced cancer medicines.

Managing Treatment Toxicities

Cancer treatments — chemotherapy, targeted agents, immunotherapy, and endocrine therapy — all carry toxicity profiles requiring proactive management. Common toxicity management principles include: dose modification grids (reduce dose for Grade 2+ toxicities; suspend for Grade 3; permanently discontinue for Grade 4 in most instances) standardised across CTCAE (Common Terminology Criteria for Adverse Events); prophylactic antiemetics before highly emetogenic chemotherapy (5-HT3 antagonists, NK1 inhibitors, dexamethasone — the triad for highly emetogenic regimens); G-CSF prophylaxis for regimens with >20% febrile neutropaenia risk; mucositis management (good oral hygiene, topical anaesthetics, sucralfate); and peripheral neuropathy monitoring with dose modification protocols.

Patient-reported outcomes — symptoms experienced and reported by patients directly — are increasingly recognised as essential quality-of-care metrics. Patient-reported nausea, fatigue, neuropathy, and quality of life scores complement objective clinical and laboratory monitoring in capturing the full clinical picture and guiding treatment modification decisions. Oncology patients should be encouraged to actively report symptoms to their care team — prompt reporting allows early intervention before toxicities escalate to treatment-limiting severity.

Infertility is an important long-term consequence of many chemotherapy regimens and hormonal therapies — particularly alkylating agents (cyclophosphamide) and GnRH agonists (leuprolide). Fertility preservation consultation (sperm banking, oocyte/embryo cryopreservation) should be offered to all cancer patients of reproductive age before starting gonadotoxic therapy — ideally before treatment begins, as the window for preservation is limited.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and oncological literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified oncologist, haematologist, physician, or specialist pharmacist. Cancer drug therapy decisions require individualised assessment by qualified oncology professionals with full knowledge of the patient’s diagnosis, staging, molecular profile, performance status, and concurrent medications. Self-diagnosis and self-treatment of cancer and serious medical conditions can be life-threatening. Always consult a qualified specialist before starting, changing, or stopping any cancer or specialty medication.